Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $61.82 +0.42 (+0.68%) (As of 12/8/2023 08:57 PM ET) Add Compare Share Share Today's Range$60.51▼$62.3050-Day Range$49.57▼$61.8252-Week Range$49.24▼$85.70Volume101,800 shsAverage Volume104,565 shsMarket Capitalization$1.07 billionP/E Ratio90.91Dividend YieldN/APrice Target$109.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside77.5% Upside$109.75 Price TargetShort InterestBearish5.67% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment-0.08Based on 2 Articles This WeekInsider TradingAcquiring Shares$237,520 Bought Last QuarterProj. Earnings Growth-28.50%From $4.21 to $3.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.67 out of 5 starsMedical Sector87th out of 942 stocksPharmaceutical Preparations Industry23rd out of 424 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $109.75, Ligand Pharmaceuticals has a forecasted upside of 77.5% from its current price of $61.82.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.67% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 6.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 1.6 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $237,520.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.19% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to decrease by -28.50% in the coming year, from $4.21 to $3.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 90.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 90.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.41.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 0.73. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesDecember 8, 2023 | finance.yahoo.comLigand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?December 6, 2023 | finance.yahoo.comLigand to Host Investor and Analyst Day on December 12, 2023 in New York CityDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 3, 2023 | americanbankingnews.comLigand Pharmaceuticals Incorporated to Post FY2023 Earnings of $4.13 Per Share, Zacks Research Forecasts (NASDAQ:LGND)December 2, 2023 | markets.businessinsider.comBuy Rating Justified by Ligand Pharma’s Strategic Investments and Promising Drug PlatformDecember 1, 2023 | finance.yahoo.comPalvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsDecember 1, 2023 | finance.yahoo.comHere's Why Ligand Pharmaceuticals (LGND) is a Strong Value StockDecember 1, 2023 | americanbankingnews.comQ1 2025 Earnings Estimate for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Issued By Zacks ResearchDecember 11, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 28, 2023 | finance.yahoo.comTharimmune (THAR) Up on Positive Data From Pipeline CandidateNovember 28, 2023 | finance.yahoo.comSermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNovember 27, 2023 | finance.yahoo.comTheseus (THRX) Up 57% in a Month on Strategic Restructuring PlanNovember 27, 2023 | finance.yahoo.comRegeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD StudyNovember 22, 2023 | msn.comHow Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 90.66%November 20, 2023 | finance.yahoo.comBayer (BAYRY) Stops Heart Drug Study Due to Lack of EfficacyNovember 16, 2023 | finance.yahoo.comChemomab (CMMB) Up on Fast Track Designation to CM-101 for PSCNovember 15, 2023 | seekingalpha.comLigand Pharmaceuticals: A Complicated TaleNovember 15, 2023 | finance.yahoo.comIntellia (NTLA) Rises on EC's Orphan Drug Tag for HAE CandidateNovember 15, 2023 | finance.yahoo.comRocket (RCKT) Surges 40% in 3 Months on Regulatory UpdatesNovember 10, 2023 | markets.businessinsider.comLigand Pharma’s Strong Financial Performance and Promising FILSPARI Sales Drive Buy RatingNovember 10, 2023 | finance.yahoo.com2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly ResultsNovember 9, 2023 | benzinga.comLigand Pharmaceuticals: Q3 Earnings InsightsNovember 9, 2023 | markets.businessinsider.comLigand Pharmaceuticals Inc Q3 Earnings SummaryNovember 9, 2023 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Ligand Pharmaceuticals Inc Earnings CallNovember 8, 2023 | finance.yahoo.comLigand Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Q3 2023 Financial Results with Increased Revenue GuidanceSee More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees76Year FoundedN/APrice Target and Rating Average Stock Price Target$109.75 High Stock Price Target$144.00 Low Stock Price Target$90.00 Potential Upside/Downside+77.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.68 Trailing P/E Ratio90.91 Forward P/E Ratio14.68 P/E Growth0.73Net Income$-33,360,000.00 Net Margins9.09% Pretax Margin46.03% Return on Equity9.67% Return on Assets8.03% Debt Debt-to-Equity RatioN/A Current Ratio16.15 Quick Ratio14.54 Sales & Book Value Annual Sales$196.24 million Price / Sales5.47 Cash Flow$5.12 per share Price / Cash Flow12.07 Book Value$35.37 per share Price / Book1.75Miscellaneous Outstanding Shares17,350,000Free Float15,550,000Market Cap$1.07 billion OptionableOptionable Beta0.92 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Todd C. Davis Ph.D. (Age 62)CEO & Director Comp: $743.49kMr. Matthew E. Korenberg (Age 48)President & COO Comp: $760.99kMr. Octavio Espinoza (Age 52)Chief Financial Officer Comp: $457.19kMr. Andrew T. Reardon J.D. (Age 48)Chief Legal Officer & Secretary Comp: $480.16kSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 54)Senior Vice President of Technical Operations & QA - Capitsol Mr. Patrick LucySenior VP & CBO Protein Expression BusinessMore ExecutivesKey CompetitorsMannKindNASDAQ:MNKDInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKArcturus TherapeuticsNASDAQ:ARCTTravere TherapeuticsNASDAQ:TVTXView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 7,295 shares on 12/6/2023Ownership: 0.051%American Century Companies Inc.Sold 12,896 shares on 11/30/2023Ownership: 0.309%Deutsche Bank AGBought 40,958 shares on 11/24/2023Ownership: 0.785%Public Sector Pension Investment BoardSold 8,963 shares on 11/22/2023Ownership: 0.116%Comerica BankBought 7,906 shares on 11/21/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price target for 2024? 4 Wall Street analysts have issued twelve-month price targets for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $90.00 to $144.00. On average, they predict the company's share price to reach $109.75 in the next year. This suggests a possible upside of 77.5% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2023? Ligand Pharmaceuticals' stock was trading at $66.80 on January 1st, 2023. Since then, LGND stock has decreased by 7.5% and is now trading at $61.82. View the best growth stocks for 2023 here. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.34. The biotechnology company earned $32.87 million during the quarter, compared to analyst estimates of $27.22 million. Ligand Pharmaceuticals had a net margin of 9.09% and a trailing twelve-month return on equity of 9.67%. The firm's quarterly revenue was down 44.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of $5.25-5.40 for the period, compared to the consensus estimate of $5.04. The company issued revenue guidance of $126-129 million, compared to the consensus revenue estimate of $126.51 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Villere ST Denis J & Co. LLC (2.53%), Chicago Capital LLC (2.08%), abrdn plc (1.85%), Rice Hall James & Associates LLC (1.63%), Northern Trust Corp (1.27%) and Invesco Ltd. (1.26%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:LGND) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.